Company Search:
Advanced Search
Sponsored Links
Hualan Biological Engineering Inc Company Snapshot
Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other companies in this sector in China: China Biologic Products Holdings Inc (2017 sales of 2.49 billion Chinese Renmimbi [US$358.63 million] of which 100% was Human Blood Product), Jinyu Bio-Technology Co Ltd (1.90 billion Chinese Renmimbi [US$273.29 million] of which 98% was Bio-Pharmaecutical), and Tonghua Dongbao Medicines Company Limited (2.54 billion Chinese Renmimbi [US$365.35 million] of which 89% was Pharmaceutical).

Sales Analysis. Hualan Biological Engineering Inc reported sales of 2.37 billion Chinese Renmimbi (US$340.45 million) for the year ending December of 2017. This represents an increase of 22.4% versus 2016, when the company's sales were 1.93 billion Chinese Renmimbi. Sales at Hualan Biological Engineering Inc have increased during each of the previous five years (and since 2012, sales have increased a total of 144%). Sales of Vaccine Products saw an increase that was more than double the company's growth rate: sales were up 157.9% in 2017, from 108.96 million Chinese Renmimbi to 280.98 million Chinese Renmimbi. Not all segments of Hualan Biological Engineering Inc experienced an increase in sales in 2017: sales of Other Operations fell 17.9% to 9.00 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Hualan Biological Engineering Inc
  Stock Performance Chart for Hualan Biological Engineering Inc
  Stock Data: Recent Stock Performance:
  Current Price (11/9/2018): 36.00
(Figures in Chinese Renmimbi)
1 Week -1.9%   13 Weeks 1.1%  
4 Weeks 10.9%   52 Weeks 22.9%  
Hualan Biological Engineering Inc Key Data:
  Ticker: 002007 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2017 Sales 2,368,176,569
(Year Ending Jan 2018).
Employees: 1,951
  Currency: Chinese Renmimbi Market Cap: 33,483,156,480
  Fiscal Yr Ends: December Shares Outstanding: 930,087,680
  Share Type: A Shares Closely Held Shares: 489,465,185
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.